Alterity Therapeutics (ATHE) reports director option expiry on ASX

Rhea-AI Filing Summary

Alterity Therapeutics Limited filed a Form 6-K furnishing an Appendix 3Y notice from the ASX that records a change in director interests for David Stamler. The filing shows that 91,392,720 unlisted options expiring on 06 January 2026 with an exercise price of $0.0320 expired and are now recorded as nil.

No ordinary shares or American Depositary Shares were acquired or disposed of, and the value/consideration for the expired options is listed as “NIL.” Stamler continues to hold fully paid ordinary shares, listed options with later expiries, further unlisted options, and 133,333 American Depositary Shares held indirectly through HSBC Custody Nominees. The Form 6-K is also incorporated by reference into several existing Form S-8 and Form F-3 registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 01/07/2026 - 08:01 AM Learn about SEC filing dates

FAQ

What does Alterity Therapeutics (ATHE) report in this Form 6-K?

The Form 6-K furnishes an ASX Appendix 3Y notice showing that director David Stamler had a large block of unlisted options expire, with no shares acquired or sold.

How many Alterity Therapeutics options held by David Stamler expired?

The notice states that 91,392,720 unlisted options expiring on 06 January 2026 with an exercise price of $0.0320 are now recorded as nil.

Did David Stamler buy or sell any Alterity Therapeutics shares?

The Appendix 3Y shows the number of shares and ADSs acquired and disposed as NIL, indicating no share purchases or sales in this update.

What Alterity Therapeutics securities does David Stamler still hold after this change?

After the option expiry, he continues to hold 11,688,312 fully paid ordinary shares, several series of listed and unlisted options with later expiries, and 133,333 American Depositary Shares held indirectly.

Is this Alterity Therapeutics Form 6-K linked to other SEC registration statements?

Yes. The company states that this Form 6-K is incorporated by reference into its existing Form S-8 and Form F-3 registration statements identified by file numbers.

What is the role of HSBC Custody Nominees in Alterity’s director holdings?

The filing notes that HSBC Custody Nominees (Australia) Limited is the registered holder of 133,333 American Depositary Shares held indirectly for David Stamler.

What is an Appendix 3Y in the context of Alterity Therapeutics?

Appendix 3Y is an ASX “Change of Director’s Interest Notice” that records updates to a director’s relevant interests in Alterity’s securities under ASX listing rule 3.19A.2.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 07, 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Change of Director's Interest Notice - D Stamler

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: January 07, 2026

2

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01  Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	David Stamler
Date of last notice	21 November 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	HSBC CUSTODY NOMINEES (AUSTRALIA)
(including registered holder)	LIMITED - 133,333 - AMERICAN DEPOSITARY SHARES
	(equivalent to 79,999,800 FULLY PAID ORDINARY SHARES)
Date of change	(1) N/A
	(2) N/A
	(3) N/A
	(4) N/A
	(5) 06 January 2026
	(6) N/A
	(7) N/A
No. of securities held prior to change	(1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT
	(2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT
	(3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT
	(4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT
	(5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT
	(6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT
	(7) 133,333 - AMERICAN DEPOSITARY SHARES
	(equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

Class	(1) FULLY PAID ORDINARY SHARES (2) LISTED OPT EXP 31/08/2026 @ $0.01 (3) LISTED OPT EXP 26/02/2027 @ $0.028 (4) UNLISTED OPT EXP 21/03/2029 @ US$0.0030 (5) UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) UNLISTED OPT EXP 08/08/2030 @ US$0.0086 (7) AMERICAN DEPOSITARY SHARES
Number acquired	(1) NIL (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL (7) NIL
Number disposed	(1) NIL (2) NIL (3) NIL (4) NIL (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) NIL (7) NIL
Value/Consideration	(1) N/A (2) N/A (3) N/A (4) N/A (5) NIL (6) N/A (7) N/A
No. of securities held after change	(1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT (5) NIL - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT (7) 133,333 - AMERICAN DEPOSITARY SHARES (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT
Nature of change	(1) N/A (2) N/A (3) N/A (4) N/A (5) Options expired (6) N/A (7) N/A

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 2

Appendix 3Y

Change of Director’s Interest Notice

Part 2 - Change of director’s relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3